[go: up one dir, main page]

PE20190350A1 - Nueva asociacion entre la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr - Google Patents

Nueva asociacion entre la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr

Info

Publication number
PE20190350A1
PE20190350A1 PE2018000094A PE2018000094A PE20190350A1 PE 20190350 A1 PE20190350 A1 PE 20190350A1 PE 2018000094 A PE2018000094 A PE 2018000094A PE 2018000094 A PE2018000094 A PE 2018000094A PE 20190350 A1 PE20190350 A1 PE 20190350A1
Authority
PE
Peru
Prior art keywords
kinase inhibitor
morpholinylmethyl
thiazolidine
pyrrol
dihydro
Prior art date
Application number
PE2018000094A
Other languages
English (en)
Inventor
Michael Frank Burbridge
Valerie Cattan
Anne Jacquet-Bescond
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20190350(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20190350A1 publication Critical patent/PE20190350A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se refiere a la asociacion entre la 3-[(3-{[4-(4-morfolinilmetil)-lH-pirrol-2-il]metilen}-2-oxo-2,3- dihidro-1H-indol-5-il)metil]-1,3-tiazolidina-2,4-diona de formula (I), o uno de sus isomeros Z o E y/o sales de adicion a un acido o a una base farmaceuticamente aceptable; y un inhibidor de tirosina quinasa del receptor del factor de crecimiento epidermico humano (EGFR) que es Gefitinib o Erlotinib. Dicha asociacion es util para el tratamiento del cancer de pulmon de celulas no pequenas en pacientes resistentes a un inhibidor de tirosina quinasa del EGFR.
PE2018000094A 2015-07-31 2016-07-29 Nueva asociacion entre la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr PE20190350A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1557412A FR3039401B1 (fr) 2015-07-31 2015-07-31 Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Publications (1)

Publication Number Publication Date
PE20190350A1 true PE20190350A1 (es) 2019-03-07

Family

ID=55299545

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000094A PE20190350A1 (es) 2015-07-31 2016-07-29 Nueva asociacion entre la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr

Country Status (40)

Country Link
US (1) US20170027952A1 (es)
EP (1) EP3124025B1 (es)
JP (2) JP2017061445A (es)
KR (1) KR101822492B1 (es)
CN (1) CN106397427A (es)
AR (1) AR105527A1 (es)
AU (1) AU2016206300A1 (es)
BR (1) BR102016017404A2 (es)
CA (1) CA2936904C (es)
CL (1) CL2018000256A1 (es)
CO (1) CO2018000953A2 (es)
CR (1) CR20180044A (es)
CU (1) CU20180013A7 (es)
CY (1) CY1120792T1 (es)
DK (1) DK3124025T3 (es)
EA (1) EA032217B1 (es)
EC (1) ECSP18003671A (es)
ES (1) ES2671133T3 (es)
FR (1) FR3039401B1 (es)
HR (1) HRP20180760T1 (es)
HU (1) HUE037632T2 (es)
IL (1) IL257232A (es)
LT (1) LT3124025T (es)
MA (1) MA39693B1 (es)
MD (1) MD3124025T2 (es)
ME (1) ME03052B (es)
MX (1) MX366748B (es)
NO (1) NO3124025T3 (es)
PE (1) PE20190350A1 (es)
PH (1) PH12016000248A1 (es)
PL (1) PL3124025T3 (es)
PT (1) PT3124025T (es)
RS (1) RS57057B1 (es)
RU (1) RU2695362C2 (es)
SG (1) SG10201605664SA (es)
SI (1) SI3124025T1 (es)
SV (1) SV2018005615A (es)
TN (1) TN2018000028A1 (es)
TW (1) TWI623315B (es)
WO (1) WO2017021634A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101956978B1 (ko) * 2015-05-18 2019-03-12 주식회사 케이티 시스템 정보 송수신 방법 및 그 장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2492864C2 (ru) * 2006-09-18 2013-09-20 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения рака, несущего мутации egfr
PT2131845E (pt) * 2007-03-01 2012-07-10 Novartis Ag Sais de adição de ácido, hidratos e polimorfos da etilamida do ácido 5-(2,4-di-hidroxi-5-isopropil-fenil)-4- (4-morfolin-4-ilmetil-fenil)-isoxazole-3-carboxílico e formulações compreendendo estas formas
JPWO2008108386A1 (ja) * 2007-03-05 2010-06-17 協和発酵キリン株式会社 医薬組成物
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP5945863B2 (ja) * 2012-01-06 2016-07-05 国立大学法人高知大学 腎細胞がん治療剤
KR20150123250A (ko) * 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
EP3091979A1 (en) * 2014-01-07 2016-11-16 Merck Patent GmbH Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib
WO2016055916A1 (en) * 2014-10-06 2016-04-14 Novartis Ag Therapeutic combination for the treatment of cancer

Also Published As

Publication number Publication date
CA2936904C (fr) 2018-12-04
AR105527A1 (es) 2017-10-11
ECSP18003671A (es) 2018-03-31
US20170027952A1 (en) 2017-02-02
SI3124025T1 (en) 2018-04-30
HRP20180760T1 (hr) 2018-06-15
PH12016000248A1 (en) 2018-01-22
SG10201605664SA (en) 2017-02-27
FR3039401B1 (fr) 2018-07-13
MX366748B (es) 2019-07-23
EA201600507A3 (ru) 2017-03-31
BR102016017404A2 (pt) 2017-02-07
DK3124025T3 (en) 2018-06-06
EP3124025B1 (fr) 2018-02-28
MA39693B1 (fr) 2018-07-31
PT3124025T (pt) 2018-04-09
JP2017061445A (ja) 2017-03-30
JP2019163306A (ja) 2019-09-26
MD3124025T2 (ro) 2018-06-30
SV2018005615A (es) 2018-05-14
EA032217B1 (ru) 2019-04-30
WO2017021634A1 (fr) 2017-02-09
KR101822492B1 (ko) 2018-01-29
NO3124025T3 (es) 2018-07-28
LT3124025T (lt) 2018-03-26
ES2671133T3 (es) 2018-06-05
MX2016009743A (es) 2017-03-03
KR20170015218A (ko) 2017-02-08
FR3039401A1 (fr) 2017-02-03
CY1120792T1 (el) 2019-12-11
ME03052B (me) 2018-10-20
TWI623315B (zh) 2018-05-11
TN2018000028A1 (fr) 2019-07-08
RS57057B1 (sr) 2018-05-31
IL257232A (en) 2018-03-29
MA39693A (fr) 2017-02-01
RU2016131395A3 (es) 2018-06-08
CO2018000953A2 (es) 2018-07-10
CR20180044A (es) 2018-04-03
RU2695362C2 (ru) 2019-07-23
TW201711686A (zh) 2017-04-01
EP3124025A1 (fr) 2017-02-01
CU20180013A7 (es) 2018-05-08
RU2016131395A (ru) 2018-02-02
PL3124025T3 (pl) 2018-06-29
EA201600507A2 (ru) 2017-02-28
AU2016206300A1 (en) 2017-02-16
CL2018000256A1 (es) 2018-04-06
CN106397427A (zh) 2017-02-15
CA2936904A1 (fr) 2017-01-31
HUE037632T2 (hu) 2018-09-28

Similar Documents

Publication Publication Date Title
GT200600394A (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis.
PE20220807A1 (es) Nuevos inhibidores de egfr
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
CO2017002714A2 (es) Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo
PE20191655A1 (es) Combinaciones farmaceuticas
CY1121248T1 (el) Πολυμορφικες μορφες κι αλατα 6-(1h-ινδολ-4-υλ)-4-(5-{[4-(1-μεθυλαιθυλο)-1-πιπεραζινυλ]μεθυλο}-1,3-οξαζολ-2-υλ)-1η-ινδαζολιου ως αναστολεις ρi3κ για χρηση στη θεραπεια π.χ. αναπνευστικων διαταραχων
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
CR20130629A (es) Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
CR20150450A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
CL2014000887A1 (es) Compuestos derivados de 1-fenil-imidazol condensado y sus sales, inhibidores de proteinas quinasas; composicion farmaceutica que los comprende; y su uso para el tratamiento de una condicion donde se desea la inhibicion de la quinasa del fgfr tal como cancer.
MX2017004129A (es) Derivado de acido 4-(4-(4-fenilureido-naftalen-1-il)oxi-piridin-2- il)amino-benzoico como inhibidor de quinasa p38.
MX382166B (es) Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos.
BR112013010564A2 (pt) compostos heterocíclicos e usos desses
NI201000059A (es) Inhibidores de la cinasa c-fms.
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
AR094997A1 (es) Sales y formas sólidas de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y composiciones que las comprenden y sus usos
EA201490543A1 (ru) Производные бициклических гетероциклов для лечения пульмонарной артериальной гипертонии
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
AR090357A1 (es) Sales de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico
BR112013021675A2 (pt) compostos de triazolopiridina como inibidores de pim cinase
BR112014003693A2 (pt) amino quinazolinas como inibidores de quinase
PE20151052A1 (es) Trans-4-{2-[4-(2,3-diclorofenil)-piperazin-1-il]-etil}-n,n-dimetilcarbamoil-ciclohexilamina para el tratamiento de sintomas negativos de la esquizofrenia
DOP2013000207A (es) Derivados de piridinilo y pirazinil-metiloxi-arilo utiles como inhibidores de la tirosina cinasa del bazo (syk)
CO2020004201A2 (es) Inhibidor del receptor del factor de crecimiento epidérmico